Cullinan Therapeutics reported cash from operations of -$38.22M and free cash flow of -$38.22M for the quarter ended Jun 2026, up 33.7% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | -18.26M | -34.21M | -12.89M | 174.06M | -24.89M | -27.09M | -58.14M | -32.21M | -39.18M | -25.56M | -37.34M | -42.03M | -40.56M | -47.65M | -48.50M | -70.06M | -50.61M | -50.71M | -49.66M | -53.70M | ||||||
| Share-based Compensation | 4.56M | 12.14M | 6.57M | 8.61M | 5.27M | 7.51M | 7.26M | 7.92M | 7.74M | 7.52M | 8.23M | 10.53M | 9.43M | 9.63M | 9.37M | 9.89M | 9.47M | 7.31M | 7.62M | 8.45M | ||||||
| Deferred Taxes | -19.57M | |||||||||||||||||||||||||
| Gains from Sales and Divestitures | 0.06M | |||||||||||||||||||||||||
| Cash from Operations | -10.55M | -15.17M | -21.91M | -25.42M | -54.35M | -24.98M | -51.00M | -31.01M | -34.14M | -18.13M | -38.25M | -36.29M | -34.14M | -36.63M | -43.16M | -57.61M | -36.88M | -38.11M | -46.05M | -38.22M | ||||||
| Depreciation, Depletion & Amortization | ||||||||||||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.06M | 0.07M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | ||||||
| Change in Working Capital | ||||||||||||||||||||||||||
| Change in Account Payables | 0.52M | 1.15M | 3.14M | -3.21M | -1.58M | 1.15M | -0.63M | 0.46M | -1.54M | 1.54M | 1.21M | -2.15M | 0.56M | -0.43M | 1.72M | -0.94M | -0.74M | -0.88M | 1.67M | 1.22M | ||||||
| Change in Accured Expenses | 1.60M | 2.77M | 1.03M | 4.69M | 1.23M | 1.58M | 2.64M | -2.82M | 5.17M | 5.06M | -7.53M | 3.60M | -0.06M | 6.89M | -5.25M | 1.61M | 5.49M | 6.18M | -4.31M | 4.21M | ||||||
| Change in Taxes | 46.50M | -35.10M | -7.12M | -0.07M | -4.21M | |||||||||||||||||||||
| Other Working Capital Changes | -0.10M | -1.83M | 1.14M | -0.09M | -0.54M | 0.62M | 0.76M | -1.92M | 3.81M | 3.29M | -0.41M | 2.59M | -1.34M | 1.64M | -1.74M | -3.52M | -0.80M | -0.84M | 0.66M | -2.09M | ||||||
| Investing Activities | ||||||||||||||||||||||||||
| Capital Expenditures | 0.25M | 0.88M | 0.16M | 0.05M | 0.01M | |||||||||||||||||||||
| Cash from Investing Activities | -25.59M | -15.86M | 34.71M | 300.85M | -57.98M | -28.61M | 15.18M | 12.11M | -42.96M | 51.47M | 12.96M | -185.11M | 19.88M | 15.96M | 36.80M | 53.40M | 67.39M | 22.39M | 32.41M | 40.68M | ||||||
| Financing Activities | ||||||||||||||||||||||||||
| Other financing activities | -0.92M | 0.02M | 1.13M | 32.13M | 3.79M | 0.66M | ||||||||||||||||||||
| Debt Issuance and Repayment | ||||||||||||||||||||||||||
| Long-Term Debt Issuances | 0.80M | 1.40M | ||||||||||||||||||||||||
| Change in Capital Stock | ||||||||||||||||||||||||||
| Net Equity Issued and Repurchased | 1.59M | 0.61M | 0.17M | 1.82M | 36.56M | 262.65M | ||||||||||||||||||||
| Misc. | ||||||||||||||||||||||||||
| Cash from Financing Activities | 0.58M | 2.70M | 3.54M | 2.01M | 1.43M | -32.91M | 1.79M | 38.60M | 0.11M | 0.25M | 1.08M | 262.20M | 1.32M | 1.58M | 0.37M | 0.71M | 0.38M | 1.10M | ||||||||
| Change in Cash | -35.56M | -28.33M | 16.34M | 277.44M | -110.91M | -86.50M | -34.02M | 19.71M | -76.99M | 33.59M | -24.21M | 40.79M | -12.94M | -19.08M | -6.35M | -3.83M | 30.52M | -15.00M | -13.25M | 3.56M | ||||||
| Free Cash Flow | -10.55M | -15.17M | -21.91M | -25.42M | -54.60M | -25.86M | -51.16M | -31.05M | -34.14M | -18.13M | -38.25M | -36.29M | -34.14M | -36.63M | -43.16M | -57.61M | -36.88M | -38.12M | -46.05M | -38.22M | ||||||
| Net Cash Flow | -35.56M | -28.33M | 16.34M | 277.44M | -110.91M | -86.50M | -34.02M | 19.71M | -76.99M | 33.59M | -24.21M | 40.79M | -12.94M | -19.08M | -6.35M | -3.83M | 30.52M | -15.00M | -13.25M | 3.56M |
Pull Cullinan Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=CGEM&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "CGEM", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=CGEM&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();